HR Execs on the Move

Regado Biosciences

www.regadobio.com

 
Regado Biosciences, Inc., is a biopharmaceutical company focused on the discovery and development of novel, oligonucleotide-based actively controllable therapeutics. Our initial focus is on applications in the acute and sub-acute cardiovascular therapeutic area. The company's lead product candidate, REG1, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen. REG1 is currently being evaluated in the REGULATE-PCI trial, a worldwide Phase 3 trial enrolling 13,200 patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI), a hospital-based procedure used to mechanically open or widen obstructed coronary ...
  • Number of Employees: 100-250
  • Annual Revenue: $100-250 Million
  • www.regadobio.com
  • 120 Mountain View Boulevard
    Basking Ridge, NJ USA 07920
  • Phone: 908.580.2100

Executives

Name Title Contact Details

Similar Companies

parteqinnovations

parteqinnovations is a Kingston, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Pharmexa-Epimmune

Pharmexa-Epimmune Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Clear Cycle

Clear Cycle is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioPharm Engineered Systems

BioPharm Engineered Systems is a Andover, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Five Prime Therapeutics

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company`s product candidates include FP-1039/GSK3052230, a protein therapeutic is in PhaseIb clinical trials for trapping and neutralizing cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation; FPA008, an antibody that inhibits colony stimulating factor-1 receptor; and FPA144 is an antibody for inhibiting FGF receptor 2b, as well as to treat patients with gastric cancer and potentially other solid tumors. It has collaboration and license agreements with GlaxoSmithKline LLC, Glaxo Group Limited, GSK-HGS, Pfizer Inc., and UCB Pharma S.A. The company was founded in 2001 and is headquartered in South San Francisco, California.